151 related articles for article (PubMed ID: 36992732)
1. BrazIliaN Type 1 & 2 DiabetEs Disease Registry (BINDER): longitudinal, real-world study of diabetes mellitus control in Brazil.
de Almeida-Pititto B; Eliaschewitz FG; de Paula MA; Ferreira GC
Front Clin Diabetes Healthc; 2022; 3():934629. PubMed ID: 36992732
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study.
Seufert J; Pfohl M; Borck A; Bramlage P; Siegmund T
Diabetes Ther; 2021 Mar; 12(3):749-764. PubMed ID: 33544356
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries.
van Mark G; Lanzinger S; Sziegoleit S; Putz FJ; Durmaz M; Borscheller M; Danne T; Seufert J; Holl RW; Bramlage P
Adv Ther; 2019 Jul; 36(7):1628-1641. PubMed ID: 31119688
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study.
Shingaki T; Taki K; Koyanagi M; Nagaoka S; Yoshizawa K; Oki N; Yoshikawa A; Imaoka T
Curr Med Res Opin; 2020 Jun; 36(6):947-958. PubMed ID: 32271092
[No Abstract] [Full Text] [Related]
6. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
7. EADSG Guidelines: Insulin Therapy in Diabetes.
Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
[TBL] [Abstract][Full Text] [Related]
8. Suboptimal glycemic control among subjects with diabetes mellitus in India: a subset analysis of cross-sectional wave-7 (2016) data from the International Diabetes Management Practices Study (IDMPS).
Ramachandran A; Jain SM; Mukherjee S; Phatak S; Pitale S; Singh SK; Agrawal N; Majumdar A; Deshpande N; Jhulka S; Minakshisundaram S; Chawla M; Lodha S; Maheshwari A; Makkar BM; Rao S; Shah P; Ghosh R; Mohanasundaram S; Menon S; Chodankar D; Kanade V; Trivedi C
Ther Adv Endocrinol Metab; 2020; 11():2042018820937217. PubMed ID: 32647562
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemia incidence and awareness among insulin-treated patients with diabetes: the HAT study in Brazil.
Lamounier RN; Geloneze B; Leite SO; Montenegro R; Zajdenverg L; Fernandes M; de Oliveira Griciunas F; Ermetice MN; Chacra AR;
Diabetol Metab Syndr; 2018; 10():83. PubMed ID: 30479669
[TBL] [Abstract][Full Text] [Related]
10. Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009-2020.
Hankosky ER; Schapiro D; Gunn KB; Lubelczyk EB; Mitroi J; Nelson DR
Diabetes Ther; 2023 Jun; 14(6):967-975. PubMed ID: 37067668
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Risk Factors for Developing Diabetic Retinopathy among Youths with Type 1 or Type 2 Diabetes throughout the United States.
Wang SY; Andrews CA; Herman WH; Gardner TW; Stein JD
Ophthalmology; 2017 Apr; 124(4):424-430. PubMed ID: 27914837
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics, Glycemic Control, and Microvascular Complications Compared Between Young-Onset Type 1 and Type 2 Diabetes Patients at Siriraj Hospital - A Tertiary Referral Center.
Preechasuk L; Tantasuwan S; Likitmaskul S; Santiprabhob J; Lertbannaphong O; Plengvidhya N; Tangjittipokin W; Nitiyanant W; Lertwattanarak R
Diabetes Metab Syndr Obes; 2022; 15():1375-1387. PubMed ID: 35528720
[TBL] [Abstract][Full Text] [Related]
13. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
14. Association Between Glycemic Control and Risk of Fracture in Diabetic Patients: A Nested Case-Control Study.
Vavanikunnel J; Charlier S; Becker C; Schneider C; Jick SS; Meier CR; Meier C
J Clin Endocrinol Metab; 2019 May; 104(5):1645-1654. PubMed ID: 30657918
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain.
Morales C; de Luis D; de Arellano AR; Ferrario MG; Lizán L
Diabetes Ther; 2015 Dec; 6(4):593-610. PubMed ID: 26589521
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.
Cummins E; Royle P; Snaith A; Greene A; Robertson L; McIntyre L; Waugh N
Health Technol Assess; 2010 Feb; 14(11):iii-iv, xi-xvi, 1-181. PubMed ID: 20223123
[TBL] [Abstract][Full Text] [Related]
17. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.
Di Dalmazi G; Coluzzi S; Baldassarre MPA; Sorbo SE; Dell'Aquila S; Febo F; Ginestra F; Graziano G; Rossi MC; Consoli A; Formoso G
Clin Ther; 2020 Sep; 42(9):1738-1749.e1. PubMed ID: 32753164
[TBL] [Abstract][Full Text] [Related]
18. Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies.
Evans M; Welsh Z; Seibold A
Diabetes Ther; 2022 Jun; 13(6):1175-1185. PubMed ID: 35476279
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
20. Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM).
Brož J; Janíčková Žďárská D; Urbanová J; Brabec M; Doničová V; Štěpánová R; Martinka E; Kvapil M
Diabetes Ther; 2018 Oct; 9(5):1897-1906. PubMed ID: 30094784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
